Kilitch shareholders back $12.9M sale of Ethiopian subsidiary
What's the deal? Kilitch DrugsDealroom has a profile for this one. Try Dealroom → (India) shareholders approved the sale of the company's entire stake in material subsidiary Kilitch Estro Biotech at an extraordinary general meeting held via video conferencing on November 16, 2026. The 50-minute session also sanctioned converting existing company debt into equity of the same subsidiary.
The numbers: Kilitch is divesting its 100% holding in the Ethiopian subsidiary to HarmeeCare Pharmaceuticals for US$14 million. After a planned US$7.74M debt-to-equity conversion, the deal yields US$12.855 million for the company.
Why now? The subsidiary generated roughly 20% of FY26 consolidated revenue but carried negative net worth. Converting debt to equity alongside the sale cleans up the balance sheet ahead of the transaction.
What's the endgame? Proceeds will reduce borrowings and support Kilitch's facility in Pen, Maharashtra. A supply and technical-services arrangement would preserve the company's commercial presence in Ethiopia.
Governance shift: Shareholders also appointed Milind Kishor Madhani and Gautam Rajan as non-executive independent directors, each for five-year terms. The meeting, chaired by managing director Mukund Mehta, drew 56 members.
What could go wrong? The sale remains subject to regulatory approvals, with completion targeted by January 2027. The EGM vote is a step forward, not a closed deal.
The signal: Kilitch's full exit from a loss-making unit — while keeping a lighter commercial footprint through a services deal — reflects a focus on balance-sheet repair and core operations over revenue scale.
Read more: scanx.trade
Image credit: Generated with Gemini